Please assess the completion status of the following clinical trial:

Trial Title: TissueLink Versus SEAMGUARD After Distal Pancreatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age equal or above 18 years~2. Accepted for elective distal pancreatectomy for any indication~Exclusion from randomization process:~* Thickness of pancreas on preoperative CT scan images \> 2.5 cm at the site of expected transection in anterior-posterior diameter. This will be reviewed by the surgeon the day before the surgeon sees the patient to predetermine the appropriateness of the patient for the study.~General study exclusion criteria:~1. Current immunosuppressive therapy~2. Chemotherapy within 2 weeks before operation~3. Bevacizumab (Avastin™) treatment not completed at least 6 weeks before operation~4. Radiotherapy before operation~5. Inability to follow the instructions given by the investigator~6. Lack of compliance~7. Persons unable or unwilling to give informed consent to participate in this study~8. Pregnant women~9. Prisoners~10. Institutionalized individuals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEAMGUARD with bioabsorbable staple (Type: ACTIVE_COMPARATOR): In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
- TissueLink with radiofrequency ablation (Type: ACTIVE_COMPARATOR): After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.

Based on this trial design, predict the completion outcome and termination type (if applicable).